Venable·FDA / LIFE SCIENCES REGULATORY
FDA Accepts Second Interchangeable Vedolizumab aBLA From Alvotech and Teva
The agency will review a subcutaneous AVT80 filing as the Entyvio biosimilar race accelerates alongside pending BPCIA litigation over Takeda's reference product.
vedolizumabbiosimilarinterchangeablealvotechtevaentyviobpciafda-acceptance
Read the original firm alert → Saturday, September 5, 2026